科研速览 · Science Skim继续刷下去 · Keep skimming →
◆ Heart Lung and Circulation2026-05-15· Medicine

Quality of Life and Function After TAVI in Adults Aged ≥90 Years: Frailty and Multimorbidity Matter

James Cameron, Benjamin Cailes, T. Lancefield, James Theuerle, Anoop N. Koshy, Matias Yudi, Louise M. Burrell, Omar Farouque, Han S. Lim, Cilla Haywood, Julian Yeoh

原始摘要(英文原文)· Original abstract
INTRODUCTION: Previous reports of transcatheter aortic valve implantation (TAVI) in adults ≥90 years emphasise procedural success and survival. Whether nonagenarians experience clinically meaningful, sustained improvements in patient-reported outcomes, and how frailty and multimorbidity may modify these benefits, remains uncertain. METHODS: We performed an exploratory single-centre retrospective cohort study of consecutive nonagenarians undergoing TAVI (January 2019 - 31 October 2024). EuroQol 5-Dimensions 3-Level (EQ-5D-3L) (including Visual Analogue Scale, VAS) and the Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) Summary Score were collected at baseline, 30 days and 12 months. Responders were defined using a ≥10-point minimally important difference. Deterioration was any negative pre- to 12-month change. Frailty was stratified into three prespecified Clinical Frailty Scale (CFS) categories: 1-3 (fit to managing well), 4-5 (vulnerable to mildly frail), and 6-9 (moderately to severely frail/terminally ill). RESULTS: Of 26 nonagenarians, 19 met inclusion criteria. Most were mildly-moderately frail (CFS 3-5: n=18; CFS 6: n=1). Median 30-day changes were +25 (IQR 10-38) for EQ-5D VAS (exact sign test p=0.001) and +39 (30-50) for KCCQ-12 (p<0.001), with gains largely sustained at 12-months (EQ-5D VAS p=0.096; KCCQ-12 p<0.001). At 12-months, 13/18 (72%) were EQ-5D VAS responders and 17/18 (94%) KCCQ-12 responders. Responder proportions were highest in less frail strata, noting CFS 6-9 contained a single patient. EQ-5D-3L problem burden improved across all domains, especially Mobility (p=0.002) and Usual activities (p=0.012). Twelve-month survival was 94% (18/19). DISCUSSION: In this single-centre nonagenarian cohort, we observed 30-day improvements in symptoms and function following TAVI that were maintained to 12 months. Observed changes appeared smaller with greater frailty and multimorbidity, and higher comorbidity burden coincided with a higher probability of deterioration. Findings should be interpreted as exploratory and hypothesis-generating.
读原文 · Read the paper ↗

AI 追问PRO

登录后使用 AI 追问

讨论区

登录后参与讨论

相关论文 · Related

Quality of Life and Function After TAVI in Adults Aged ≥90 Years: Frailty and Multimorbidity Matter — 科研速览 Science Skim